SPECIAL NOTICE
99 -- Sole Source Study to Establish Timing of the reversal of coagulopathy following hemorrhagic shock using small volume 7.5% NaCl with Adenocaine Mg2+
- Notice Date
- 4/16/2012
- Notice Type
- Special Notice
- Contracting Office
- N62645 Naval Medical Logistics Command 693 Neiman Street Ft. Detrick, MD
- ZIP Code
- 00000
- Solicitation Number
- N3239812DOBSON
- Archive Date
- 5/2/2012
- Small Business Set-Aside
- N/A
- Description
- The Naval Medical Logistics Command (NMLC) intends to award a sole source contract under the authority of FAR 6.302-1 to Hibernation Therapeutics Pty Ltd; Queensland, Australia 4811, for the collaborative study with Naval Medical Research Center (NMRC), to establish the timing of the correction of coagulopathy using small volume 7.5% NaCl with Adenocaine Mg2+ following severe blood loss in the robust preclinical rat model of hemorrhagic shock. A mechanistic study using the ROTEM and multiplate Platelet functional analysis will be performed in a rat model of severe hemorrhagic shock which may have important battlefield and clinical applications. Studies will include plasma aPTT and PT clotting times, and whole blood ROTEM clotting and platelet functions. These studies will be conducted concurrently to test different, potentially effective small volume resuscitation strategies to not only raise mean arterial pressure into the permissive range but to correct the hypocoagulopathy that occurs accompanying shock and blood loss. A comprehensive understanding of the mechanisms of acute coagulopathy along with small volume resuscitation has far reaching practical battlefield applications and may fill an urgent military capability gap. Additionally, evaluation and characterization of the clotting mechanisms in the robust rat model of hemorrhagic shock will provide essential baseline data for translation into larger battlefield relevant models and human safety trials. The estimated value of the contract is $200,000.00. HT demonstrates a unique and innovative concept and a unique capability of the source to provide the particular research services proposed, as no other vendors are capable of performing this work due to the patent and proprietary nature of the medication used in the study. Based on these unique capabilities and the previous research accomplished, HT is the only institution capable of meeting the Government ™s requirements. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All capability statements received by 4:00 PM Eastern Time, 1 MAY 2012 will be considered by the Government. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to NMLC-Research@med.navy.mil.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DON/BUMED/N62645/N3239812DOBSON/listing.html)
- Record
- SN02722863-W 20120418/120416234710-0683ee19406f70f0710a396ffcd1d614 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |